Jump to content

Mesoridazine: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
CheMoBot (talk | contribs)
Updating {{drugbox}} (changes to verified fields - added verified revid - updated '') per Chem/Drugbox validation (report errors or bugs)
BogBot (talk | contribs)
m replaced secondary with primary DrugBank accession number per talk
Line 31: Line 31:
| PubChem = 4078
| PubChem = 4078
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = APRD00610
| DrugBank = DB00933
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3936
| ChemSpiderID = 3936

Revision as of 17:40, 13 April 2012

Mesoridazine
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa682306
Routes of
administration
oral, intravenous
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding4%
MetabolismHepatic/Renal
Elimination half-life24 to 48 hours
ExcretionBiliary and renal
Identifiers
  • 10-{2-[(RS)1-Methylpiperidin-2-yl]ethyl}- 2-methylsulfinyl- 10H-phenothiazine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H26N2OS2
Molar mass386.576 g/mol g·mol−1
3D model (JSmol)
Melting point130 °C (266 °F)
Solubility in waterinsoluble mg/mL (20 °C)
  • O=S(c2cc1N(c3c(Sc1cc2)cccc3)CCC4N(C)CCCC4)C
  • InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3 checkY
  • Key:SLVMESMUVMCQIY-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Mesoridazine (Serentil) is a piperidine neuroleptic drug belonging to the class of drugs called phenothiazines, used in the treatment of schizophrenia. It is a metabolite of thioridazine. The name is partially derived from the MEthyl-SulfOxy group in the structure.

It has central antiadrenergic, antidopaminergic, antiserotonergic and weak muscarinic anticholinergic effects.

Serious side effects include akathisia, tardive dyskinesia and the potentially fatal neuroleptic malignant syndrome.

Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.[1]

Chemistry

Mesoridazine (10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylsufinyl)phenothiazine) is synthesized by an analogous scheme to that seen already for thioridazine.

However, it is also synthesized by alkylating the acidic form of 2-methylthiophenothiazine -methylsulfonylphenothiazine- using 2-(2-chloroethyl)-1-methylpiperidine. 2-methylthiophenothiazine is initially acylated at the nitrogen atom using acetic anhydride, giving 10-acetyl-2-methylthiophenothiazine. The resulting acetyl derivative is further oxidized by hydrogen peroxide into 10-acetyl-2-methylsulfonylpenothiazine. Deacylation of this product in potassium carbonate methanol solution gives 2-methylsulfanylphenothiazine, which is alkylated by 2-(2-chlorethyl)-1-methylpiperidine in the presence of sodamide, affording the desired mesoridazine.

References

  1. ^ [1]